AarogyaAI Secures $700,000 in Seed Funding for AI-Driven Antibiotic Development
Delhi-based healthtech startup AarogyaAI has secured $700,000 in seed funding, led by Redstart Labs and Avaana Capital. The funding round, which closed in January 2022, also saw participation from existing investors Entrepreneur First (EF) and First In Ventures.
Founded in 2019 by Praapti Jayaswal and Avlokita Tiwari, AarogyaAI operates on a B2B2C model, serving diagnostic labs, hospitals, and pharmaceuticals. The startup uses AI and machine learning to analyze DNA sequences, generating drug susceptibility reports for antibiotic development. With the new funding, AarogyaAI plans to expand its team, validate its platform, and deploy pilots. Additionally, the company is developing dashboard analytics to showcase disease demographics and drug resistance patterns. AarogyaAI aims to provide insights into antibiotic development as it gathers more data.
The seed funding, amounting to $700,000, will be used by AarogyaAI for research and development, team expansion, validation, and pilot deployments. The startup's innovative approach to drug-resistant tuberculosis diagnosis has attracted significant investment, positioning it for growth in the healthtech sector.
